Forte Biosciences, Inc. logo

Forte Biosciences, Inc. (FBRX)

Market Open
27 Aug, 20:00
NASDAQ (CM) NASDAQ (CM)
$
76. 99
0
0%
$
1.58B Market Cap
- P/E Ratio
- Div Yield
1.4M Volume
- Eps
$ 76.99
Previous Close
Add Transaction
Day Range
76.97 76.99
Year Range
10.11 77.2
Want to track FBRX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

FBRX trading today higher at $76.99, an increase of 0% from yesterday's close, completing a monthly increase of 0.4043% or $0.31. Over the past 12 months, FBRX stock gained 182.8435%.
FBRX is not paying dividends to its shareholders.
The last earnings report, released on May 13, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.74%, based on the last three reports.
Forte Biosciences, Inc. has completed 2 stock splits, with the recent split occurring on Aug 28, 2024.
The company's stock is traded on 4 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).

FBRX Chart

People also search for

Astrana Health Inc.
$ 38.55
+1.1674%
Purecycle Technologies, Inc. Warrant
$ 2.39
-7.0078%
OmniAb Inc.
$ 0.25
-3.8462%
Alpha Tau Medical Ltd. Warrant
$ 3.31
-8.0556%
PNT
POINT Biopharma Global Inc.
$ 12.5
+0.1603%
Forte Biosciences shares surge after argenx agrees to acquire company for $2.2B

Forte Biosciences shares surge after argenx agrees to acquire company for $2.2B

Forte Biosciences (NASDAQ:FBRX) shares surged about 40% to around $76 on Monday after argenx (NASDAQ:ARGX) announced an agreement to acquire the biotechnology company in a deal valued at approximately $2.2 billion. Under the terms of the agreement, argenx will acquire all outstanding Forte Biosciences shares for $77 per share in cash.

Proactiveinvestors | 1 month ago
FBRX Stock Rallies 78% on Positive Early-Stage Vitiligo Study Data

FBRX Stock Rallies 78% on Positive Early-Stage Vitiligo Study Data

Forte Biosciences stock soars after early-stage data show FB102 significantly improves facial depigmentation in vitiligo with a favorable safety profile.

Zacks | 1 month ago
Forte Biosciences' FB102 Hits Key Goal in Vitiligo Study, Shows Durable Improvement

Forte Biosciences' FB102 Hits Key Goal in Vitiligo Study, Shows Durable Improvement

Forte Biosciences NASDAQ: FBRX said FB102 showed statistically significant improvement in a small placebo-controlled vitiligo study, with Chief Executive Officer Paul Wagner highlighting continued improvement after patients stopped treatment as a key feature of the results.

Marketbeat | 1 month ago

Forte Biosciences, Inc. Investors

Name Quantity Cost Value Profit ($) Gain (%)
NA
Nizar Araji National Bank Of Canada /FI/
572 $14,488.4 $43,923.88 $29,435.48 203.17%
Joseph Castro
Joseph Castro Nuveen LLC
108,347 $2.3M $8.32M $6.02M 261.51%
Li Peng
Li Peng China Universal Asset Management Co. Ltd.
8,000 $170,560 $612,800 $442,240 259.29%
Hui Fai Tam
Hui Fai Tam Caitong International Asset Management Co. Ltd.
113 $2,401 $8,656.93 $6,255.93 260.56%
Mark Schafer
Mark Schafer Police & Firemen's Retirement System of New Jersey
5,712 $121,380 $437,539.2 $316,159.2 260.47%

Forte Biosciences, Inc. (FBRX) FAQ

What is the stock price today?

The current price is $76.99.

On which exchange is it traded?

Forte Biosciences, Inc. is listed on NASDAQ (CM).

What is its stock symbol?

The ticker symbol is FBRX.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 1.58B.

Has Forte Biosciences, Inc. ever had a stock split?

Forte Biosciences, Inc. had 2 splits and the recent split was on Aug 28, 2024.

Forte Biosciences, Inc. Profile

Biotechnology Industry
Healthcare Sector
Paul A. Wagner CEO
NASDAQ (CM) Exchange
34962G208 CUSIP
US Country
23 Employees
16 Jun 2020 Last Dividend
28 Aug 2024 Last Split
- IPO Date
Forte Biosciences, Inc. is a U.S.-based biopharmaceutical company currently in its clinical development phase. The firm's key initiative involves advancing the FB-102 program, which is designed to tackle a variety of autoimmune conditions, notably vitiligo and alopecia areata. Their main offices are situated in Dallas, Texas.

Contact Information

Address: 3060 Pegasus Park Drive
Phone: 310 618 6994